Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542135 · ClinicalTrials.gov registry record · Phase 2
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
A Phase 2 study, sponsored by Alison Stopeck.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT04542135 is a Phase 2 study that has completed, run by Alison Stopeck. The registered enrollment target is 62 participants.
The verdict
NCT04542135, a Phase 2 study, has completed, sponsored by Alison Stopeck.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
Interventions
- DRUG Placebo
- DRUG Sulindac Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2025-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542135
The ClinicalTrials.gov registry entry for NCT04542135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alison Stopeck, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04542135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542135 about?
NCT04542135 is a clinical study titled "Sulindac and Breast Density in Women at Risk of Developing Breast Cancer". The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
What is the current status of trial NCT04542135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2020-11-20. Estimated completion is 2025-05-19.
What interventions are being tested in trial NCT04542135?
The interventions under investigation include: Placebo (DRUG), Sulindac Pill (DRUG).
Who is sponsoring clinical trial NCT04542135?
This trial is sponsored by Alison Stopeck, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.